INNOVA BIOTECH SOLUTIONSVisit Website →
← Back to blog

Cut Attrition: Lead Prioritization for R&D With Five Criteria and FEP

September 7, 2026
Cut Attrition: Lead Prioritization for R&D With Five Criteria and FEP

Prioritize leads with a data-driven, multi-parameter score that weighs potency, selectivity, physicochemical properties, ADME/PK, and early safety, then have a medicinal chemist audit the ranking before any compound gets synthesis budget. Ligand efficiency and FEP predictions accurate to roughly 1 kcal/mol belong in that score, but so does human judgment, as Innova Biotech Solutions has found across dozens of hit-to-lead engagements. What follows is the checklist, the scoring math, the computational shortcuts, and the experiments that make this workable.

TL;DR:

  • Prioritize compounds with a clear, multi-parameter score that includes potency, selectivity, physicochemical properties, ADME/PK, and safety, with human review before synthesis.
  • Use ligand efficiency alongside raw potency to avoid optimizing compounds that are large and greasy but have weak developability prospects.
  • Build a reproducible scoring model by selecting specific metrics, normalizing data, assigning context-dependent weights, and keeping individual domain scores visible during aggregation.
  • Apply computational tools like FEP for close analog ranking within about 1 kcal/mol accuracy, but always supplement them with human judgment and uncertainty assessments.
  • Implement a gate-based workflow involving initial triage, ADME screening, safety testing, and final scoring review, leveraging virtual screening and contracted services for efficiency.
Innovabiotech
Prioritize Leads With Scientific Precision
Innova Biotech Solutions provides tailored bioinformatics and biotechnology support for virtual screening, hit to lead optimization, and related projects.
Explore Innova Biotech Solutions

Table of Contents

What Are the Core Criteria for Lead Prioritization?

Five domains decide whether a compound deserves synthesis and assay budget: in vitro potency, selectivity, physicochemical properties, ADME/PK, and early safety. Skip any one of them and you find out the hard way, usually after months of medicinal chemistry work on a series that dies in a hERG panel or a microsomal stability assay.

A workable starting checklist looks like this:

  • Potency: potent activity against the primary target, with a defined assay window and confirmed dose-response curve, not a single-point screen result.
  • Selectivity: greater than 10-fold selectivity against the closest off-target or paralog; infectious disease and kinase programs often need to push that bar to 100-fold or more.
  • Physicochemical properties: molecular weight, logP, and polar surface area inside standard drug-like ranges, plus a ligand efficiency value that flags whether potency is coming from genuine binding or just molecular bulk.
  • ADME/PK: measurable metabolic stability and permeability data, not a prediction alone.
  • Early safety: a clean read on the most common attrition drivers, hERG and mutagenicity, before you commit to a scaffold.

Ligand efficiency deserves special attention here. Reviews of hit-to-lead failures consistently point to overweighting raw potency while ignoring efficiency and drug-likeness, and that pattern shows up again and again in late-stage attrition data. A compound that hits IC50 of 5 nM by being large and greasy is a worse bet than one at 200 nM with a clean efficiency profile, because the second one still has room to improve without breaking developability. Missing this at the checklist stage is not a minor inefficiency. It is how programs spend eighteen months optimizing a series that was never going to clear a PK gate.

How Do You Build a Reproducible Lead Scoring Model?

A composite score turns the checklist into something you can rank, defend, and revisit. The pipeline has four steps, and skipping any of them is how scoring systems become political rather than predictive.

  1. Select metrics. Pick five to eight measurable parameters, no more, tied directly to the checklist domains above.
  2. Normalize. Convert raw values (IC50, logP, clearance) into 0 to 1 desirability scores using functions that reflect real preference, not raw linear scaling. Ligand efficiency normalization works better than absolute potency normalization because it corrects for molecular size automatically.
  3. Weight. Assign weights that reflect program risk. A CNS program weights permeability and logP heavily; an oncology combination program weights selectivity and hERG risk higher.
  4. Aggregate. Combine into a single composite score, but keep the individual domain scores visible alongside it. A hidden aggregate hides exactly the tradeoff a chemist needs to see.

Pro Tip: Never let a composite score auto-rank without a confidence flag. When two or more inputs are missing or come from a low-throughput assay, mark that compound's score as provisional rather than letting it silently rank alongside fully characterized molecules.

Governance matters more than the math. Someone, usually the project's lead medicinal chemist and a computational lead jointly, needs to own the weights and sign off on any recalibration. Flexible, multiattribute approaches that get revisited every few DMTA cycles consistently outperform a static scoring function set once at project kickoff and never touched again.

Where Do FEP, ML, and Active Learning Actually Help?

Computational methods are triage tools, not verdicts. Used correctly, they cut the number of compounds that need a full assay panel before you know whether they're worth the resources.

  • FEP and TI predict relative binding affinity within roughly 1 kcal/mol of experimental values, which makes them genuinely useful for ranking close analogs, the kind that differ by a methyl group or a halogen swap, where a wrong call costs a synthesis cycle.
  • Gradient boosting machines and comparable classifiers can triage HTS hit lists, separating likely true positives from assay artifacts before confirmatory work begins.
  • Active learning picks the next batch of compounds to synthesize based on where the model is most uncertain, which keeps DMTA cycles from wasting synthesis on redundant chemical space.

None of these tools should make the final call alone. Model outputs need provenance and uncertainty estimates attached: what data trained the model, how confident is this specific prediction, and what happens when the compound falls outside the training distribution. A prioritization score built on an opaque model is a liability the first time a chemist asks why a compound ranked where it did and nobody can answer.

Which Assays Belong in an Early Screening Panel?

Run experiments in two tiers so you're not committing full PK studies to compounds that haven't earned them yet.

  1. Confirmatory potency and selectivity. Retest HTS hits in dose-response format against the primary target and the nearest off-targets before anything else.
  2. Rapid ADME snapshot. A rapid in vivo PK read, sometimes called a snapshot or cassette approach, paired with in vitro microsomal stability and a permeability assay (PAMPA or Caco-2) gives a fast developability read without committing to full animal studies.
  3. Early safety flags. hERG and Ames testing catch the two most common late-stage killers before a series gets too far into optimization.
  4. Minimal off-target panel. A focused selectivity screen against the two or three most biologically relevant related targets, not an exhaustive kinome-wide sweep at this stage.

Sample quantities for early ADME panels are typically small, allowing parallel testing with potency confirmation. Compounds with clear liabilities in early hERG or Ames tests are deprioritized to conserve resources. No composite score should be able to override a clean toxicophore flag.

How Do You Balance Exploration and Exploitation in DMTA?

Every DMTA cycle forces a choice: exploit compounds that look good already, or explore chemical space that might reveal something better — a classic example of the exploration/exploitation tradeoffs detailed in lead nurturing explained: Boost conversions with effective strategies. Lean too hard on exploitation and you optimize a mediocre scaffold to its ceiling. Lean too hard on exploration and you never converge on a nominatable candidate.

  • Track selection performance with a retrieval metric, something like top-5 or top-1 retrieval rate against a known-good set, to see whether your current strategy is actually finding the best molecules.
  • Before committing a synthesis budget to a new strategy, run a retrospective simulation on a legacy dataset. Benchmarks on real historical series show that certain strategies retrieve roughly 85% of top-tier molecules within the top 5% of ranked candidates, which tells you a lot about whether a scoring approach is worth trusting on your live project.
  • Set stopping rules ahead of time: a defined composite-score band plus a clean early-safety read triggers advancement; a compound below the band after two optimization cycles gets deprioritized, not carried forward on hope.

Pro Tip: Run the retrospective simulation on your own legacy series, not a public benchmark. Your historical hit-to-lead data already contains the answer to whether a given weighting scheme would have picked your best compound first.

What Does a Practical Prioritization Workflow Look Like?

A working gate structure keeps a hit-to-lead program moving without letting weak compounds drift forward on momentum alone.

  1. Gate 1, initial triage. HTS confirmation plus computational pre-filtering. Owner: computational lead. Timeline: one to two weeks.
  2. Gate 2, ADME/PK screening. Rapid PK snapshot, microsomal stability, permeability. Owner: DMPK lead. Timeline: two to three weeks.
  3. Gate 3, confirmatory biology and safety. Dose-response selectivity, hERG, Ames. Owner: biology lead. Timeline: three to four weeks.
  4. Gate 4, lead nomination. Composite score review plus medicinal chemistry sign-off. Owner: project team jointly.

Virtual screening and focused libraries can compress Gates 1 and 2 significantly. On cost, NIH historical guidance puts cumulative spend to reach an initial decision point in the low millions of dollars range, a useful anchor when justifying budget for early screening infrastructure rather than skimping on it.

Operationalizing Prioritization With Innova Biotech Solutions

Some service providers run pipelines similar to the one this guide describes: virtual screening and structure-based triage feeding a hit-to-lead optimization process, with computational modeling for affinity ranking and protein and peptide design support for biologic and peptide programs. Teams working through DMTA cycles get computational peptide screening support and binding affinity prediction built into the same workflow described above, with medicinal chemists reviewing every model output before it reaches a decision gate.

Three Lessons From Watching Prioritization Programs Succeed and Fail

ADME and safety screening earns its place early, not after a series is already optimized for potency. Composite scores are decision support, never a decision. And medicinal chemistry judgment stays at the center of every gate, no matter how good the model gets. If you lead an R&D team, spend two weeks this quarter running a retrospective simulation on one legacy series before trusting a new scoring scheme on a live program.

— Hooman

Let Innova Biotech Solutions Run Your Prioritization Pipeline

Building a reproducible, auditable scoring pipeline takes computational infrastructure and medicinal chemistry time most R&D teams can't spare mid-project. Certain service providers operationalize the checklist and scoring framework covered here, running virtual screening, FEP-based affinity ranking, and hit-to-lead triage as contracted engagements, often with a chemist reviewing ranked outputs before delivery to clients.

Innovabiotech

If you're weighing which compounds in an active series deserve the next round of synthesis budget, start a project inquiry with Innova Biotech Solutions and get a scoped proposal built around your specific target class and timeline.

Sources

FAQ

What Is Lead Prioritization in Drug Discovery?

Lead prioritization is the process of ranking hit or lead compounds across potency, selectivity, physicochemical properties, ADME/PK, and early safety to decide which ones advance into optimization.

What Is Ligand Efficiency and Why Does It Matter?

Ligand efficiency measures binding potency relative to molecular size, and it predicts developability better than raw potency alone, which is why it belongs in any scoring checklist.

How Accurate Is FEP for Predicting Binding Affinity?

Free energy perturbation methods typically predict binding affinity within about 1 kcal/mol of experimental values, making them reliable for ranking closely related analogs rather than distant chemotypes.

Should ML Models Make the Final Prioritization Decision?

No. ML and computational scores should inform ranking, but a medicinal chemist should review every model-derived score, with provenance and uncertainty data attached before any go/no-go decision.

How Can a Company Get Help Running a Prioritization Workflow?

Teams without in-house computational capacity can work with a service provider like Innova Biotech Solutions, which runs virtual screening, hit-to-lead optimization, and scoring pipelines as a contracted engagement.